Robert Lorne Hopfner - 02 Jun 2021 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Reporting relationship: Director
Issuer ticker: PCVX
Reported as of: 02 Jun 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Jun 2021, 18:51:50 UTC
Next SEC filing: 24 Jun 2021
Source filing: View source filing
Reporting owner signature: /s/ Ron Metzger, Attorney-in-Fact

Key filing fact

Robert Lorne Hopfner filed Form 4 for Vaxcyte, Inc. (PCVX) on 03 Jun 2021.

Key facts

This page summarizes Robert Lorne Hopfner's Form 4 filing for Vaxcyte, Inc. (PCVX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Jun 2021, 18:51.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PCVX transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: -15,000
Change %: -50%
Price: $0.000000
Shares after: 15,000
Date: 02 Jun 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,000
Exercise price: $21.49
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to the option will vest monthly and fully vest on the earlier of June 2, 2022 or the day prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date.